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Edited by Laszlo NagyAbstract Recent studies have shown that adiponectin, an adipo-
cyte-derived cytokine, acts as a potent inhibitor of inﬂammatory
responses. It has been also demonstrated that bacterial and viral
signalings in host cells are triggered via Toll-like receptor (TLR)
molecules. Therefore, in the present study, we investigated
whether globular adiponectin (gAd) would be able to inhibit
TLR-mediated nuclear factor-jB (NF-jB) signaling in mouse
macrophages (RAW264). gAd predominantly bound to the Adi-
poR1 receptor and suppressed TLR-mediated NF-jB signaling.
gAd-mediated inhibition of TLR-mediated IjB phosphorylation
and NF-jB activation was eliminated by the pretreatment of
cycloheximide. Also their inhibitions of gAd were blocked by
preincubation of the cells with an antibody against AdipoR1,
but not with an antibody against AdipoR2. Taken together, these
ﬁndings indicate that adiponectin negatively regulates macro-
phage-like cell response to TLR ligands via an unknown endog-
enous product(s).
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Adiponectin, a 30-kDa adipocyte complement-related pro-
tein (ACRP30), is an adipocyte-derived hormone. Although
adiponectin is abundantly present in plasma of healthy hu-
mans (1.9–17 lg/ml) [1], interestingly, it has been shown that
the levels of adiponectin mRNA and its protein in plasma
are decreased in obesity and type 2 diabetes [2,3]. Adiponectin
consists of two structurally distinct domains, an amino-termi-
nal collagen-like domain and a carboxyl-terminal globular do-Abbreviations: ACRP30, a 30-kDa adipocyte complement-related
protein; CpG, deoxycytidylate-phosphate-deoxyguanylate; FBS, fetal
bovine serum; gAd, globular adiponectin; GST, glutathione S-trans-
ferase; IjB, inhibitor jB; LPS, lipopolysaccharide; LTA, lipoteichoic
acid; NF-jB, nuclear factor-jB; NIK, NF-jB-inducing kinase; ODN,
oligodeoxynucleotide; RT-PCR, reverse transcriptase-PCR; TLR,
Toll-like receptor; TNF-a, tumor necrosis factor alpha
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doi:10.1016/j.febslet.2005.11.019main. Fruebis et al. [4] detected both the globular domain of
adiponectin (gAd) and the full-length form of adiponectin in
mammalian plasma. They also demonstrated that gAd exhibits
much more potent biological activities than the full-length
adiponectin.
Recent studies have shown that adiponectin is involved in
the modulation of inﬂammatory responses by inhibiting the
proliferation of myelomonocytic cells [5] and that the hormone
also suppresses tumor necrosis factor alpha (TNF-a)-mediated
inﬂammatory responses in human aortic endothelial cells [6].
Adiponectin is also able to inhibit the phagocytic activity of
and lipopolysaccharide (LPS)-stimulated TNF-a production
in macrophages [5]. Together, these observations suggest that
adiponectin acts as a potent anti-inﬂammatory cytokine.
Importantly, many studies [7–9] have demonstrated that intra-
cellular signaling induced by microorganism cell components is
triggered by their binding to members of the Toll-like receptor
(TLR) family. However, since it has not been demonstrated
whether adiponectin acts as a negative regulator of TLR-med-
iated signaling, it is very important to demonstrate this point;
because such a demonstration would suggest a novel action of
adiponectin in the host defense mechanism. Furthermore,
although several researchers have suggested that obesity is a
potential risk factor of wound infection, the precious mecha-
nisms by which obese patients are predisposed to wound infec-
tion are not known [10–13]. It is possible that adiponectin will
function as a regulatory factor of bacterial infections via TLRs
in obese subjects.
We investigated herein, using murine macrophage-like cells
(RAW264), whether gAd negatively regulates the intracellular
signaling induced by three diﬀerent Toll-like receptors (TLR2,
TLR4 and TLR9). Our data suggest a novel function of adipo-
nectin as a potent negative regulator of the TLR-signaling
pathway.2. Materials and methods
2.1. Cells and reagents
Murine macrophage-like cell line RAW264 (RCB0535; RIKEN Cell
Bank, Ibaragi, Japan) was maintained in RPMI 1640 medium (Sigma–
Aldrich Corp., St. Louis, MO, USA) supplemented with 10% fetal
bovine serum (FBS; Thermo Trace Ltd., Melbourne, Australia),
2 mM L-glutamine, and 50 lg/ml gentamicin. The murine preadipocyte
cell line 3T3-L1 (JCRB9014) was purchased from Health Science
Research Resources Bank (Osaka, Japan) and its cells were grown inblished by Elsevier B.V. All rights reserved.
Fig. 1. RT-PCR analysis of mouse adiponectin receptors (AdipoR1
and AdipoR2), adiponectin, and b-actin in RAW264 and 3T3-L1 cells.
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ing 10% FBS, 2 mM L-glutamine, and 50 lg/ml gentamicin. Cultures
were maintained at 37 C under 5% CO2.
Lipopolysccharide from Escherichia coli O111:B4 (LPS), lipoteichoic
acid from Bacillus subtilis (LTA), and cycloheximide were purchased
from Sigma–Aldrich Corp. An oligodeoxynucleotide (ODN) contain-
ing the proper deoxycytidylate-phosphate-deoxyguanylate (CpG)-
DNA motif was commercially synthesized by Operon Biotechnologies,
Inc. (Tokyo, Japan). The sequence of the ODN was TCCAT-
GACGTTCCTGATGCT [14]. Rabbit anti-mouse AdipoR1 antibody
and rabbit anti-mouse AdipoR2 antibody were obtained from Alpha
Diagnostic International (San Antonio, TX, USA).
2.2. Puriﬁcation of recombinant protein
Glutathione S-transferase (GST) fusion vector [pGEX-6P-1 (Amer-
sham Biosiences Corps., Piscataway, NJ, USA)] containing the globu-
lar domain of mouse ACRP30 (gACRP30) was provided by Dr. I.
Shimomura (Osaka University, Osaka, Japan). Recombinant gAd
was prepared as described previously [15]. Brieﬂy, GST-gACRP30 pro-
tein was produced in E. coli strain BL21 and puriﬁed with glutathione
Sepharose 4B (Amersham Biosiences Corps.). GST was cleaved from
GST-gACRP30 protein by PreScission Protease (Amersham Bio-
siences Corps.). The isolated protein was applied to an Aﬃ-Prep poly-
myxin column (Bio-Rad Laboratories, Heracules, CA, USA) to
remove endotoxin contaminants as described previously [16].
2.3. Reverse transcriptase (RT)-PCR
Total RNA (5 lg) from RAW264 cells or 3T3-L1 cells was isolated
by using the TRIzol reagent (Invitrogen Corp., Carlsbad, CA, USA).
The RNA samples were reverse-transcribed to cDNA by use of
Ready-To-Go You-Prime First-Strand Beads (Amersham Biosciences
Corps.), and the cDNAs for AdipoR1/R2 and adiponectin were ampli-
ﬁed by PCR. PCR primers were partly designed from recently pub-
lished sequences [17,18] and were as follow: AdipoR1 forward
primer, 5 0-ACGTTGGAGAGTCATCCCGTAT-3 0, AdipoR1 reverse
primer, 5 0-CTCTGTGTGGATGCGGAAGAT-3 0 (product size:
130 bp); AdipoR2 forward primer, 5 0-TCCCAGGAAGATGA-
AGGGTTTAT-3 0, AdipoR2 reverse primer, 5 0-TTCCATTCGTTC-
CATAGCATGA-3 0 (product size: 60 bp); adiponectin forward primer,
5 0-GCCCAGTCATGCCGAAGA-3 0, adiponectin reverse primer, 5 0-
TCTCCAGCCCCACACTGAAC-3 0 (product size: 332 bp); b-actin
forward primer, 5 0-ATGGATGACGATATCGCT-3 0, b-actin reverse
primer, 5 0-ATGAGGTAGTCTGTCAGGT-30 (product size: 588 bp).
The resulting ampliﬁcation products were electrophoresed on a
12.5% acrylamide gel and stained with ethidium bromide. The bands
were visualized by illumination with UV light.
2.4. Adiponectin binding assay
gAd biotinylation with NHS-LC-biotin (Pierce Chemical, Rockford,
IL, USA) and ﬂow cytometric analysis of gAd binding to RAW264
cells were performed as described by Yamaguchi et al. [19].
2.5. NF-jB luciferase assay
RAW264 cells (2 · 106) were incubated with a mixture of
pTKjB2Luc (reporter gene, 8 ng), pRL-TK (internal control, 2 ng),
and PolyFect transfection reagent (80 ll, QIAGEN K.K., Tokyo,
Japan) for 24 h in 10-cm plastic plates with RPMI 1640 medium con-
taining 10% FBS. The cells were harvested, cultured in a 24-well plastic
plate, and preincubated with the desired amounts of gAd, and then
were treated or not for an additional 6 h with a stimulant. Thereafter,
the treated cells were lysed with Passive Lysis Buﬀer (Promega, Mad-
ison, WI, USA). The Dual-Luciferase Reporter Assay System (Prome-
ga) was used to quantify the expression of the ﬁreﬂy luciferase and
Renilla luciferase. The ﬁreﬂy luciferase was normalized to the Renilla
and presented as values relative to the control.
2.6. Western blotting
Whole-cell lysates (20 lg of protein) were resolved on 12.5% SDS–
PAGE gels, and then electrophoretically transferred to nitrocellulose
membranes. Immunoblotting was performed as described previously
[20]. The membranes were ﬁrst exposed to primary antibodies, and
then to secondary antibodies conjugated with horseradish peroxidase.
The primary antibodies used were anti-phospho-IjB-a (Ser32) anti-body, anti-IjB-a antibody (Cell Signaling Technology, Inc.; Beverly,
MA, USA), and anti-actin antibody (MP Biomedicals, Inc.; Aurora,
OH, USA).
2.7. Statistical analysis
Comparisons between groups were performed by using Tukeys mul-
tiple range tests. Statistical diﬀerence was indicated by P < 0.05. Stu-
dents t-test was used to determine the statistical signiﬁcance of
diﬀerences between results obtained for the gAd-pretreated groups ver-
sus those for the cycloheximide and gAd-pretreated group.3. Results
3.1. Adiponectin receptor mRNA levels in RAW264 and 3T3L1
cells
Since it is of importance to know whether RAW264 and
3T3L1 cells used in this study constitutively express adiponec-
tin and its two diﬀerent receptors (AdipoR1 and AdipoR2),
ﬁrstly using RT-PCR we examined the expression of these
genes at the mRNA level. As shown in Fig. 1, adiponectin,
AdipoR1, and AdipoR2 genes were expressed in both types
of cells.
3.2. Binding of gAd to RAW264 cells via AdipoR1
Our next interest was to address whether adiponectin could
directly bind to adiponectin receptors on the cells. Therefore,
we analyzed, by use of ﬂow cytometry, the binding of gAd
to RAW264 cells. The association of biotinylated gAd to
RAW264 cells occurred in a saturable manner over a physio-
logical concentration range (2.5–30 lg/ml) of gAd (Fig. 2A).
Importantly, we observed that the saturable binding of gAd
to RAW264 cells was dramatically inhibited by pretreatment
of the cells with anti-AdipoR1 antibody. However, such inhib-
itory action was not observed when anti-AdipoR2 antibody
was used (Fig. 2B). On the other hand, although data not
shown, the binding of gAd to the cells was also signiﬁcantly
inhibited by pretreating the cytokine with anti-gAd antibody.
Together, these observations suggest that gAd predominantly
bound to AdipoR1 on RAW264 cells, not to AdipoR2.
3.3. gAd inhibition of TLR ligands-induced NF-jB activation
Many recent studies [8,21,22] have demonstrated that cell
components of microorganisms including bacteria, viruses,
fungi, and so on are recognized by TLR family receptors
Fig. 2. Binding of gAd to RAW264 cells. (A) RAW264 cells (106) were incubated for 30 min at 37 C with 2.5–30 lg/ml biotinylated gAd. The cells
were then washed with Hanks balanced salt solution, stained with streptavidin-phycoerythrin for 15 min at room temperature, and analyzed by ﬂow
cytometry. Data are shown as the means ± S.D. (B) Eﬀect of anti-adiponectin receptor antibodies on binding of gAd to RAW264 cells. The cells (106)
were pretreated with 10 lg/ml anti-mouse AdipoR1 antibody, anti-mouse AdipoR2 antibody or non-immune rabbit IgG for 1 h at 37 C. The cells
were then incubated for 30 min at 37 C with 10 lg/ml biotinylated gAd. The results are expressed as the means ± S.D. Representative results from 3
experiments are shown.
Fig. 3. Attenuation of NF-jB-induced reporter gene activity by gAd
in RAW264 cells. The cells were pretreated with gAd (5–20 lg/ml) for
6 h before the addition of LPS (0.3 lg/ml, closed bars), LTA (5 lg/ml,
meshed bars), or CpG-DNA (25 lg/ml, open bars) for 6 h. Then, the
cells were harvested and luciferase activities were analyzed by using a
Dual-Luciferase Reporter Assay System. Activity was expressed
relative to the untreated control. Values represent means ± S.D. for
triplicate cultures. The experiments were performed three times, and
similar results were obtained in each experiment. *,P < 0.05 versus
basal LPS-induced NF-jB activity; §,P < 0.05 versus basal LTA-
#
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Although several recent studies [5,6,23] have suggested that
adiponectin acts as a potent anti-inﬂammatory cytokine, it
had still not been known whether the cytokine is able to regu-
late negatively TLR-mediated intracellular signaling pathways.
Therefore, it was of interest to us to explore this possibility.
Firstly, we measured LPS-induced NF-jB activity in
RAW264 cells by conducting a luciferase assay. Although
the data are not shown, LPS induced the highest NF-jB activ-
ity in RAW264 cells at 6 h after initiation of LPS treatment at
0.3 lg/ml in the presence of 10% FBS. Under these culture con-
ditions, we examined whether gAd could inhibit this LPS-
induced NF-jB activity. Consequently, we observed that gAd
markedly inhibited LPS-induced NF-jB activity when the cells
were pretreated for 6 h with the cytokine fragment (Fig. 3). In
addition, we wanted to know whether gAd could also inhibit
NF-jB activity in RAW264 cells when such activity was in-
duced via other TLRs. Therefore, using LTA and CpG, which
are ligands of TLR2 and 9, respectively, we examined whether
gAd would inhibit NF-jB activation induced by them. As ex-
pected, gAd pretreatment signiﬁcantly inhibited LTA- and
CpG-induced NF-jB activation in a dose-dependent manner
(Fig. 3).induced NF-jB activity; ,P < 0.05 versus basal CpG-induced NF-jB
activity.3.4. Eﬀect of cycloheximide on the gAd inhibition of LPS-
induced NF-jB activation
Also we considered it is very important to address whether
the gAd-mediated inhibition of TLR intracellular signaling oc-
curred directly or indirectly via some endogenous product(s).
Therefore, we examined the eﬀect of cycloheximide on the inhi-
bition by gAd. The cells were pretreated or not with the pro-
tein synthesis inhibitor at 20 ng/ml for 1 h prior to gAd
treatment and subsequently incubated in the presence or
absence of LPS (0.3 lg/ml) for 6 h. Then, we measured LPS-
induced NF-jB activation under these conditions. Conse-
quently, we observed that the cycloheximide pretreatment
signiﬁcantly blocked the inhibitory action of gAd (Fig. 4).
These observations suggest that some endogenous product
may be involved in the gAd inhibitory action toward LPS-
induced NF-jB activity.3.5. gAd inhibition of LPS-induced IjB phosphorylation
To determine if this unknown endogenous product might act
to block the phosphorylation of IjB, thereby preventing NF-
jB transport to the nucleus, we explored the eﬀect of cyclohex-
imide on inhibitory action of gAd for IjB phosphorylation in
LPS-treated RAW264 cells. Fig. 5 shows that although the
peak of LPS-stimulated IjB-a phosphorylation was observed
at 10 min after LPS addition, gAd pretreatment signiﬁcantly
inhibited the LPS-stimulated IjB-a phosphorylation. Impor-
tantly, as shown in Fig. 6, the inhibitor of protein synthesis
clearly blocked the inhibitory eﬀect of gAd on phosphorylation
of IjB-a in LPS-treated cells. The gAd treatment alone had no
eﬀect on the IjB phosphorylation (data not shown). These
observations strongly support our suggestion that some gAd-
Fig. 4. Pretreatment with cycloheximide blocks the inhibitory eﬀects
of gAd on LPS-induced NF-jB activation. The cells were pretreated or
not with cycloheximide (CHX; 20 ng/ml) for 1 h prior to gAd
treatment. They were then treated with gAd (20 lg/ml) for 6 h and
washed. After the culture medium had been replaced with fresh
medium, the cells were stimulated with LPS (0.3 lg/ml) for an
additional 6 h. Data are shown as the means ± S.E. of the means for
three experiments performed with triplicate cultures. *,P < 0.05
comparing the gAd-treated group with the cycloheximide and gAd-
pretreated group.
Fig. 5. Eﬀects of gAd on LPS-induced signaling in RAW264 cells.
Time courses of phosphorylation of IjB (top) and IjB (middle)
induced by LPS (0.3 lg/ml) without gAd or with 20 lg/ml of gAd.
Actin levels (bottom) are also shown. Whole-cell lysates were
immunoblotted with anti-phospho-IjB-a antibody, anti-IjB-a anti-
body or anti-actin antibody. Relative band intensities were determined
by using NIH Image version 1.62 software. The values below the bands
are the mean fold increases in the expression levels of RAW264 cells
incubated with LPS compared with that of unstimulated RAW264
cells.
Fig. 6. Pretreatment with cycloheximide blocks the inhibitory eﬀects
of gAd on LPS-induced IjB phosphorylation. The cells were
pretreated or not with cycloheximide (CHX; 20 ng/ml) for 1 h prior
to gAd (20 lg/ml) for 6 h, and then stimulated with LPS (0.3 lg/ml) for
10 min. Then the cells were lysed with detergent (1% Nonidet P-40 in
0.15 M NaCl). The proteins from each cell lysate were electrophoresed
on a 12.5% SDS gel. After the proteins on the gels had been blotted
onto nitrocellulose membranes, ﬂuorographs were developed after
incubation (overnight at 4 C) with either anti-phospho-IjB-a anti-
body, anti-IjB-a antibody or anti-actin antibody. Relative band
intensities were determined by using NIH Image version 1.62 software.
The values below the bands are the mean fold increases in the
expression levels of RAW264 cells incubated with LPS, gAd and CHX
compared with that of unstimulated RAW264 cells.
Fig. 7. Anti-AdipoR1 antibody blocks gAd-mediated inhibition of
LPS-induced NF-jB activation. The cells were pretreated with 10 lg/
ml of normal rabbit IgG, 10 lg/ml of anti-AdipoR1 antibody, or
10 lg/ml of anti-AdipoR2 antibody for 1 h at 37 C, and were then
incubated with 20 lg/ml gAd for 6 h. After having been washed with
phosphate-buﬀered saline and replaced with fresh medium, the cells
were stimulated with 0.3 lg/ml LPS for 6 h at 37 C. NF-jB activity
was measured by using a Dual-Luciferase Reporter Assay System.
Activity was expressed relative to the untreated control. Data are
shown as the means ± S.E. of the means for three experiments
performed in triplicate. *,P < 0.05 versus the other groups.
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tion of IjB, thereby inhibiting NF-jB activation in LPS-trea-
ted cells.
3.6. gAd inhibits LPS-induced NF-jB activation and IjB
phosphorylation via AdipoR1
We have already shown that gAd binding to RAW264 cells
is dramatically inhibited by pretreating the cells with anti-Adi-
poR1 antibody, but not with anti-AdipoR2 antibody (Fig. 2B).
Therefore, we explored which receptor is involved in the gAd-
mediated inhibition of LPS-induced NF-jB activation and IjB
phosphorylation. As shown in Figs. 7 and 8, although anti-
AdipoR1 antibody signiﬁcantly blocked the inhibitory eﬀects
of gAd, such signiﬁcant inhibition was not observed with
anti-AdipoR2 antibody. These results suggest that gAd inhibi-
tion of TLR-mediated NF-jB signaling is predominantly med-
iated via AdipoR1.4. Discussion
In the present study, we demonstrated that gAd clearly
inhibited LTA, LPS, and CpG DNA-induced NF-jB activa-
tion in RAW264 cells. Interestingly, this observation suggests
that gAd acts as a negative regulator of TLR-mediated inﬂam-
matory responses.
Recently, two adiponectin receptors (AdipoR1 and Adi-
poR2) were cloned [17]. AdipoR1 is abundantly expressed in
Fig. 8. Anti-AdipoR1 antibody blocks gAd-mediated inhibition of
LPS-induced IjB phosphorylation. The cells were pretreated with
10 lg/ml of normal rabbit IgG, 10 lg/ml of anti-AdipoR1 antibody, or
10 lg/ml of anti-AdipoR2 antibody for 1 h prior to gAd (20 lg/ml) for
6 h, and then stimulated with LPS (0.3 lg/ml) for 10 min. Whole-cell
lysates were immunoblotted with anti-phospho-IjB-a antibody or
anti-actin antibody. Relative band intensities were determined by using
NIH Image version 1.62 software. The values below the bands are the
mean fold increases in the expression levels of RAW264 cells incubated
with LPS, gAd and each antibody compared with that of unstimulated
RAW264 cells.
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[24,25] and as a low-aﬃnity receptor for full-length adiponec-
tin, whereas AdipoR2 is predominantly found in liver and
serves as an intermediate-aﬃnity receptor for both forms of
adiponectin [17]. Although we observed that our anti-AdipoR1
antibody completely inhibited the binding of gAd to RAW264
cells and blocked gAd-mediated inhibition of TLR-mediated
IjB phosphorylation and NF-jB activation, the AdipoR2
antibody had no such eﬀects. Therefore, these observations
suggest that AdipoR1 is the predominant receptor for the
binding of gAd to RAW264 cells (Fig. 2B) and may play an
important role in adiponectin signaling of macrophages (Figs.
7 and 8).
Several investigations [26,27] have demonstrated that TLRs
initiate their signaling cascade via the sequential recruitment of
MyD88, IRAK, and TRAF6, which in turn activate down-
stream mediators such as mitogen-activated protein kinase
and NF-jB, though Akira et al. [28] also showed the existence
of a MyD88-independent signaling pathway of TLR. Since
TLR-mediated signaling pathways are strongly involved in
both the initiation and progression of inﬂammatory responses
induced by microbial infections, it is very important to deﬁne
the negative regulatory molecule(s) of TLR-mediated signaling
cascades. Regarding this point, several studies [29–33] have
actually identiﬁed negative molecules such as IRAKM,
SOCS1, Tollip, SIGIRR, A20 and so on. Therefore, our inter-
est was to explore gAd as another inhibitor of this TLR-med-
iated signaling.
We herein showed that gAd acted as a potent inhibitor of
TLR-induced signaling in RAW264 cells (Fig. 3). Since we
found that gAd-mediated inhibition of TLR-induced NF-jB
activity and IjB phosphorylation in RAW264 cells was pre-
vented by pretreatment with cycloheximide (Figs. 4 and 6),
some endogenous protein(s) may be involved in this inhibition
by gAd. Therefore, it is of interest to explore in a future study
what proteins are endogenously induced in gAd-treated cells
and how they function to inhibit the TLR signaling pathway.
NF-jB-inducing kinase (NIK) phosphorylates the IjB ki-
nase complex, leading to IjB phosphorylation and subsequent
NF-jB activation [34]. gAd speciﬁcally suppressed TLRfamily-induced NF-jB activation of the IjB-a–NF-jB path-
way, suggesting that the target molecule of gAd inhibition of
the TLR family-induced NF-jB signaling pathway may be
one of the signaling molecules that act between NIK and
IjB-a.
Furthermore, a recent study has suggested that obesity is
one of the risk factors for developing postoperative mediastini-
tis (POM) due to Staphylococcus aureus [10]. The association
between obesity and risk for POM has been demonstrated
[11–13]. Since adiponectin levels in plasma are decreased in
obesity, it is interesting to note the possibility that therapeutic
applications of adiponectin could function as a negative regu-
lator against microbial infections via TLRs in obese patients.
In conclusion, the data presented herein suggest that gAd
acts as a potent negative regulator of macrophage-like cell re-
sponses to TLR ligands via a newly synthesized endogenous
product(s). Our present results also suggest a novel function
of adiponectin as an anti-inﬂammatory molecule acting in bac-
terial and virus infections.Acknowledgments: We thank Drs. I. Shimomura and N. Maeda for
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